Erlotinib in pancreatic cancer: Are tumor cells the (only) target? [2]

Journal of Clinical Oncology

Volumn 25, Issue 36, 2007, Pages 5836-5837

  Normanno, Nicola ^a   de Luca, Antonella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE;

CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG NON SMALL CELL CANCER; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR CELL;

ANTINEOPLASTIC AGENTS; HUMANS; PANCREATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 37649015342     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.6258     Document Type: Letter

References (18)

1. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
2. Löhr M, Kloppel G, Maisonneuve P, et al: Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: A meta-analysis. Neoplasia 7:17-23, 2005
3. Moore MJ, da Cunha Santos G, Kamel-Reid S, et al: The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. J Clin Oncol 25:202s, 2007 (suppl; abstr 4521)
4. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
5. Massarelli E, Varella-Garcia M, Tang X, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896, 2007
6. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995, 2006
7. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
8. Normanno N, Bianco C, De Luca A, et al: Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment. Endocr Relat Cancer 10:1-21, 2003
9. Bruns CJ, Solorzano CC, Harbison MT, et al: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926-2935, 2000
10. Baker CH, Kedar D, McCarty MF, et al: Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 161:929-938, 2002
11. Weber KL, Doucet M, Price JE, et al: Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63:2940-2947, 2003
12. Yokoi K, Sasaki T, Bucana CD, et al: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65:10371-10380, 2005
13. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
14. Kim SJ, Uehara H, Karashima T, et al: Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9:1200-1210, 2003
15. Baker CH, Pino MS, Fidler IJ: Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors. Neoplasia 8:470-476, 2006
16. Hirata A, Ogawa S, Kometani T, et al: ZD1839 (Iressa) induces anti-angiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62:2554-2560, 2002
17. Sini P, Wyder L, Schnell C, et al: The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 11:4521-4532, 2005
18. Kindler HL, Niedzwiecki D, Hollis D, et al: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). ASCO Meeting Abstracts 25:199s, 2007 (suppl; abstr 4508)